FindTrial
Sign In

modified vaccinia virus ankara vaccine expressing p53

BIOLOGICAL4 trials

Sponsors

City of Hope Medical Center

Conditions

Adult Solid NeoplasmBladder CarcinomaColon CarcinomaEstrogen Receptor NegativeHER2/Neu NegativeHead and Neck Squamous Cell CarcinomaHepatocellular CarcinomaMelanoma

Phase 1

Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer
CompletedNCT01191684
City of Hope Medical CenterRecurrent Colon Cancer, Recurrent Gastric Cancer, Recurrent Pancreatic Cancer +9
Start: 2011-10-31End: 2013-08-31Updated: 2017-08-01
p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer
CompletedNCT02275039
City of Hope Medical CenterRecurrent Fallopian Tube Carcinoma, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Carcinoma
Start: 2015-01-31End: 2018-04-23Updated: 2018-04-30
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
Active, not recruitingNCT02432963
City of Hope Medical CenterAdult Solid Neoplasm, Bladder Carcinoma, Colon Carcinoma +14
Start: 2016-06-14End: 2026-10-02Updated: 2026-01-28

Phase 2

P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Active, not recruitingNCT03113487
City of Hope Medical CenterRecurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma
Start: 2018-02-01End: 2027-04-08Updated: 2026-07-16

Related Papers

CF33-hNIS-anti-PD-L1 oncolytic virus followed by trastuzumab-deruxtecan in a patient with metastatic triple negative breast cancer: a case study.
2023-11-104 citations
Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies
Journal for ImmunoTherapy of Cancer2019-08-2230 citations
A phase 1 study of p53MVA vaccine in combination with pembrolizumab.
Journal of Clinical Oncology2018-02-1014 citations
A phase I study of a p53MVA vaccine in combination with gemcitabine (GEM) in recurrent ovarian cancer (OC).
Journal of Clinical Oncology2016-05-201 citations